Omeros Corporation
NASDAQ:OMER
8.9 (USD) • At close January 15, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Omeros Corporation |
Symbool | OMER |
Munteenheid | USD |
Prijs | 8.9 |
Beurswaarde | 515,753,220 |
Dividendpercentage | 0% |
52-weken bereik | 2.61 - 13.6 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Gregory A. Demopulos M.D. |
Website | https://www.omeros.com |
An error occurred while fetching data.
Over Omeros Corporation
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)